ECSP088623A - Derivados de azepinoindol como agentes farmacéuticos - Google Patents

Derivados de azepinoindol como agentes farmacéuticos

Info

Publication number
ECSP088623A
ECSP088623A EC2008008623A ECSP088623A ECSP088623A EC SP088623 A ECSP088623 A EC SP088623A EC 2008008623 A EC2008008623 A EC 2008008623A EC SP088623 A ECSP088623 A EC SP088623A EC SP088623 A ECSP088623 A EC SP088623A
Authority
EC
Ecuador
Prior art keywords
azepinoindol
derivatives
pharmaceutical agents
affinity
compounds
Prior art date
Application number
EC2008008623A
Other languages
English (en)
Inventor
Raju Mohan
Wei Xu
Richard Martin
Brenton T Flatt
Xiao-Hui Gu
Brett Busch
Tie-Ling Wang
Jason H Wu
Longcheng Wang
Taegon Baik
Chris A Buhr
Diva Sze-Ming Chan
Vasu Jammalamadaka
Richard George Khoury
Katherine Lara
Sunghoon Ma
Jason Jevious Parks
John M Nuss
Bryan K S Yeung
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of ECSP088623A publication Critical patent/ECSP088623A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se relaciona con compuestos de la fórmula I, que presentan afinidad para el receptor farnesoide X.
EC2008008623A 2005-12-15 2008-07-14 Derivados de azepinoindol como agentes farmacéuticos ECSP088623A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75067905P 2005-12-15 2005-12-15
US75063405P 2005-12-15 2005-12-15

Publications (1)

Publication Number Publication Date
ECSP088623A true ECSP088623A (es) 2008-08-29

Family

ID=37946206

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008623A ECSP088623A (es) 2005-12-15 2008-07-14 Derivados de azepinoindol como agentes farmacéuticos

Country Status (13)

Country Link
US (1) US20090203577A1 (es)
EP (1) EP1963331A1 (es)
JP (2) JP5420908B2 (es)
AR (1) AR058781A1 (es)
AU (1) AU2006325815B2 (es)
BR (1) BRPI0620156A2 (es)
CA (1) CA2633243C (es)
EC (1) ECSP088623A (es)
IL (1) IL191907A0 (es)
PE (1) PE20071100A1 (es)
RU (1) RU2008128823A (es)
TW (1) TW200745124A (es)
WO (1) WO2007070796A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004259009A1 (en) * 2003-07-23 2005-02-03 Exelixis, Inc. Azepine derivatives as pharmaceutical agents
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR101614723B1 (ko) 2008-01-11 2016-04-22 알바니 몰레큘라 리써치, 인크. Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
PL2271613T3 (pl) * 2008-03-27 2014-09-30 Gruenenthal Gmbh Hydroksymetylocykloheksyloaminy
CN103183630A (zh) 2008-03-27 2013-07-03 格吕伦塔尔有限公司 取代的4-氨基环己烷衍生物
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2334681A1 (en) * 2008-09-26 2011-06-22 Wyeth LLC 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
JP2012532144A (ja) 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ITRM20100329A1 (it) * 2010-06-15 2011-12-16 Franco Baldelli Modulazione del recettore nucleare per i farnesoidi (fxr) con molecole agoniste per la prevenzione e trattamento di fenomeni aterosclerotici indotti da somministrazione di inibitori delle proteasi
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CA2942403A1 (en) * 2014-03-13 2015-09-17 Salk Institute For Biological Studies Fxr agonists and methods for making and using
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
RU2021100040A (ru) * 2014-12-22 2021-02-02 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
BR112017020374A2 (pt) * 2015-03-26 2018-06-05 Akarna Therapeutics Ltd compostos bicíclicos fundidos para o tratamento de doença
WO2017078928A1 (en) * 2015-11-06 2017-05-11 Salk Institute For Biological Studies Fxr agonists and methods for making and using
WO2017143134A1 (en) * 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
EP3468962A1 (en) 2016-06-13 2019-04-17 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
EP4424364A3 (en) 2017-03-28 2024-11-27 Gilead Sciences, Inc. Methods of treating liver disease
PT3612520T (pt) 2017-04-12 2022-01-06 Il Dong Pharma Derivados de isoxazol como agonistas de recetores nucleares e utilizações dos mesmos
AU2020209564B2 (en) 2019-01-15 2022-12-01 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
CN118388474A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663935A1 (fr) * 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
MY122278A (en) * 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
AU2004259009A1 (en) * 2003-07-23 2005-02-03 Exelixis, Inc. Azepine derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
CA2633243A1 (en) 2007-06-21
PE20071100A1 (es) 2007-12-21
CA2633243C (en) 2014-05-27
EP1963331A1 (en) 2008-09-03
AR058781A1 (es) 2008-02-20
AU2006325815A1 (en) 2007-06-21
BRPI0620156A2 (pt) 2011-12-20
US20090203577A1 (en) 2009-08-13
WO2007070796A1 (en) 2007-06-21
RU2008128823A (ru) 2010-01-20
TW200745124A (en) 2007-12-16
AU2006325815B2 (en) 2012-07-05
IL191907A0 (en) 2008-12-29
JP2009519964A (ja) 2009-05-21
JP2014028829A (ja) 2014-02-13
JP5420908B2 (ja) 2014-02-19

Similar Documents

Publication Publication Date Title
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
BRPI0818672A2 (pt) 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase
GT201000376A (es) Compuestos organicos
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
GT200900027A (es) Compuestos organicos
MX2010009646A (es) Agentes terapeuticos antivirales.
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CO6310993A2 (es) Moleculas utiles para el control de insectos
CO6341625A2 (es) Derivados de indol como agentes anticáncer
PA8792401A1 (es) Fenilendiaminas
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
CY1113820T1 (el) Παραγωγα 4-αλκοξυπυριδαζινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
BRPI0607309A2 (pt) processos para a preparação de fenilpirazol uréias substituìdas
PA8667201A1 (es) Nuevos compuestos farmaceuticos
CR11273A (es) Derivados-2-ona disustituidos en 3, su preparacion y su aplicacion en terapeutica
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
CO6531479A2 (es) Derivados de espirolactama y uso de los mismos
UY30052A1 (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
BRPI0821611A8 (pt) Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
GT200600017A (es) 4-feniltetrahidroisoquinolinas sustituidas, proceso para su preparacion, su uso como medicamento y medicamento que las comprende